The effects of canagliflozin on heart failure and cardiovascular death by baseline participant characteristics: Analysis of the CREDENCE trial.
Arnott C, Li JW, Cannon CP, de Zeeuw D, Neuen BL, Heerspink HJL, Charytan DM, Agarwal A, Huffman MD, Figtree GA, Bakris G, Chang TI, Feng K, Rosenthal N, Zinman B, Jardine MJ, Perkovic V, Neal B, Mahaffey KW.
Arnott C, et al. Among authors: neuen bl.
Diabetes Obes Metab. 2021 Jul;23(7):1652-1659. doi: 10.1111/dom.14386. Epub 2021 Apr 16.
Diabetes Obes Metab. 2021.
PMID: 33769679